<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/12/2022 7:46:50 PM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 53042cb5-dfdc-416a-b50a-4177d22d5562 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:fbio="http://www.fortressbiotech.com/20220512" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityCentralIndexKey" id="Tc_zgmFLAMTe027RRSMBuvglg_1_1">0001429260</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:AmendmentFlag" id="Tc_iO9vLJCOkEuLEn9JqVZNXg_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fbio-20220512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0CtkpXka8EeO1V76ajlKPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_tr9QRJmNAUS4yMI5BMQcDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="color:#212529;font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="color:#212529;font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3c42373e_2355_4dcf_84f2_b28b46a08600"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:DocumentType" id="Narr_in_0t1dCCUuqBp_dcwPlEA"><b style="color:#212529;font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="color:#212529;font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">Date of report (Date of earliest event reported):&#160;</span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:DocumentPeriodEndDate" id="Narr_l5o1LIEUjUGKn-K-_zTsqQ"><b style="color:#212529;font-weight:bold;">May 12, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityRegistrantName" id="Narr_W5Ob8oYXJ06H5pzEcf3T6g"><b style="color:#212529;font-weight:bold;">Fortress Biotech,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="color:#212529;">(Exact Name of Registrant as Specified in Charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityIncorporationStateCountryCode" id="Narr_mWx8ZW25ck6EJaOSW6itlg"><b style="color:#212529;font-weight:bold;">Delaware</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;"><br /></b><b style="color:#212529;font-weight:bold;">&#160;</b><span style="color:#212529;">(State or Other Jurisdiction</span><span style="color:#212529;"><br /></span><span style="color:#212529;">of Incorporation)</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#212529;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;width:32.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityFileNumber" id="Narr_3iK5Vh2V2UCZvLVoRavfeA"><b style="color:#212529;font-weight:bold;">001-35366</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;"><br /></b><b style="color:#212529;font-weight:bold;">&#160;</b><span style="color:#212529;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#212529;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityTaxIdentificationNumber" id="Narr_qbOrZ4ZXiEedKNgk_OUYaw"><b style="color:#212529;font-weight:bold;">20-5157386</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;"><br /></b><span style="color:#212529;">(IRS Employer</span><span style="color:#212529;"><br /></span><span style="color:#212529;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityAddressAddressLine1" id="Narr_jq5BOniy0kShcQXaauCJWA"><b style="color:#212529;font-weight:bold;">2 Gansevoort Street</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;">,&#160;</b><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityAddressAddressLine2" id="Narr_3kPZBcr500WoMUo4Hh7RrA"><b style="color:#212529;font-weight:bold;">9th Floor</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityAddressCityOrTown" id="Narr_ENarLELz0UuPKdpF-EBq5w"><b style="color:#212529;font-weight:bold;">New York</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;">,&#160;</b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityAddressStateOrProvince" id="Narr_MAFnFi0MjkezETvPtDW44Q"><b style="color:#212529;font-weight:bold;">New York</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;">&#160;</b><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityAddressPostalZipCode" id="Narr_SHUWg9ipokKycexMDkfCPQ"><b style="color:#212529;font-weight:bold;">10014</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">(Address of Principal Executive Offices)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="color:#212529;font-weight:bold;text-decoration-color:#212529;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:CityAreaCode" id="Narr_H76DyECthUKwiKdq8JEVhw"><b style="color:#212529;font-weight:bold;text-decoration-color:#212529;text-decoration-line:underline;text-decoration-style:solid;">781</b></ix:nonNumeric><b style="color:#212529;font-weight:bold;text-decoration-color:#212529;text-decoration-line:underline;text-decoration-style:solid;">)&#160;</b><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:LocalPhoneNumber" id="Narr_Xb2lPpyrykasD0FlcYrEOw"><b style="color:#212529;font-weight:bold;text-decoration-color:#212529;text-decoration-line:underline;text-decoration-style:solid;">652-4500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="color:#212529;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:WrittenCommunications" id="Narr_af5wlVB6JEq5hLG0-thnwQ"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="color:#212529;">Written communications pursuant to Rule&#160;425 under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:SolicitingMaterial" id="Narr_oz0RHuKDpk2PyyTGsdWKqQ"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="color:#212529;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:PreCommencementTenderOffer" id="Narr_XWTcFAuVd0Glgj_H1IMgdA"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="color:#212529;">Pre-commencement communications pursuant to Rule&#160;14d-2b under the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:PreCommencementIssuerTenderOffer" id="Narr_go9F5_BEx0SnZmR5Y0reIA"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="color:#212529;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="color:#212529;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_52c3350a_51df_4a24_be07_3c1c2314c092"></a><a id="Tc_dDM6CqDSRU-NMsJrcuafjQ_1_0"></a><a id="Tc_wJVJbtiNEEibyEmV4BhIIg_1_1"></a><a id="Tc_cDZ_ezkDCkaRqfy1JnmmsA_1_2"></a><a id="Tc_7wxmAEd8tUOU-t__rnZWVQ_2_2"></a><a id="Tc_N5vIK-T9cUeUphjRId2nRw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.096847534%;padding-left:0pt;padding-right:0pt;width:100.19%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.28%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:21.73%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:38.28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="color:#212529;">Title of each class</span></p></td><td style="vertical-align:top;width:21.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="color:#212529;">Trading Symbol(s)</span></p></td><td style="vertical-align:top;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="color:#212529;">Name of each exchange on which registered</span></p></td></tr><tr><td style="vertical-align:middle;width:38.28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0CtkpXka8EeO1V76ajlKPA" name="dei:Security12bTitle" id="Tc_idGS_w5K4Uu5gMIbU2kGhw_2_0"><span style="color:#212529;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:21.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0CtkpXka8EeO1V76ajlKPA" name="dei:TradingSymbol" id="Tc_KwfU6PgDIk6thfEEyRvX5Q_2_1"><span style="color:#212529;">FBIO</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0CtkpXka8EeO1V76ajlKPA" name="dei:SecurityExchangeName" id="Narr_7zUxi5KCdk-qjPSyoX39JQ"><span style="color:#212529;">Nasdaq</span></ix:nonNumeric><span style="color:#212529;"> Capital Market</span></p></td></tr><tr><td style="vertical-align:middle;width:38.28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_tr9QRJmNAUS4yMI5BMQcDw" name="dei:Security12bTitle" id="Tc_eSi1QT8cF0qooTzqsbKbAA_3_0"><span style="color:#212529;">9.375% Series A Cumulative Redeemable Perpetual Preferred Stock</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:21.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_tr9QRJmNAUS4yMI5BMQcDw" name="dei:TradingSymbol" id="Tc_w37S1ZjhFUaavSYHN2Vlbg_3_1"><span style="color:#212529;">FBIOP</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_tr9QRJmNAUS4yMI5BMQcDw" name="dei:SecurityExchangeName" id="Narr_HjP2-7uGH0WlMDb7ee7c4g"><span style="color:#212529;">Nasdaq</span></ix:nonNumeric><span style="color:#212529;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><span style="color:#212529;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_5_12_2022_To_5_12_2022_BB7yJ1aCcEmhsjBtI1zA_Q" name="dei:EntityEmergingGrowthCompany" id="Narr_0UDdTsjprEadx6TNGXqDHA"><span style="color:#212529;font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="color:#212529;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#212529;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, Fortress Biotech, Inc. issued a press release to announce financial results and recent corporate highlights for the quarter ended March 31, 2022. A copy of such press release is being furnished as Exhibit 99.1 to this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">(d)&#160;&#160;&#160;&#160;Exhibits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following exhibit is furnished herewith:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.33%;border-top:1px solid #000000;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.6%;border-top:1px solid #000000;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="fbio-20220512xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release issued by Fortress Biotech, Inc., dated May 12, 2022.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.6%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit&#160;101)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">Fortress Biotech,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">(Registrant)</span></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Date: May 12, 2022</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#212529;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">By:</span></p></td><td style="vertical-align:bottom;width:46.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">/s/&#160;Lindsay&#160;A.&#160;Rosenwald,&#160;M.D.</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">&#160;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">&#160;</span></p></td><td style="vertical-align:bottom;width:46.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Lindsay A. Rosenwald, M.D.</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">&#160;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">&#160;</span></p></td><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Chairman, President and Chief Executive Officer</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "fbio-20220512x8k.htm", "description": "8-K", "secsgml_size_bytes": 36883}]
{"company-data": {"conformed-name": "Fortress Biotech, Inc.", "cik": "0001429260", "assigned-sic": "2834", "irs-number": "205157386", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35366", "film-number": "22918019"}, "business-address": {"street1": "1111 KANE CONCOURSE", "street2": "SUITE 301", "city": "BAY HARBOR ISLANDS", "state": "FL", "zip": "33154", "phone": "781-652-4500"}, "mail-address": {"street1": "1111 KANE CONCOURSE", "street2": "SUITE 301", "city": "BAY HARBOR ISLANDS", "state": "FL", "zip": "33154"}, "former-company": {"former-conformed-name": "CORONADO BIOSCIENCES INC", "date-changed": "20080310"}}
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 12, 2022
Fortress Biotech, Inc.
(Exact Name of Registrant as Specified in Charter)
​
Delaware
(State or Other Jurisdiction
of Incorporation)
001-35366
(Commission File Number)
20-5157386
(IRS Employer
Identification No.)
​
2 Gansevoort Street
,
9th Floor
New York
,
New York
10014
(Address of Principal Executive Offices)
(
781
)
652-4500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act.
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
☐
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
​
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
FBIO
Nasdaq
Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FBIOP
Nasdaq
Capital Market
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 2.02.    Results of Operations and Financial Condition.
On May 12, 2022, Fortress Biotech, Inc. issued a press release to announce financial results and recent corporate highlights for the quarter ended March 31, 2022. A copy of such press release is being furnished as Exhibit 99.1 to this report.
The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits.
The following exhibit is furnished herewith:
Exhibit
Number
Description
99.1
Press Release issued by Fortress Biotech, Inc., dated May 12, 2022.
104
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
Fortress Biotech, Inc.
​
(Registrant)
​
​
Date: May 12, 2022
​
​
​
By:
/s/ Lindsay A. Rosenwald, M.D.
Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive Officer
​
​
​
​
​